Cancer Drugs Treatment and Toxicity 2023
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2408
Special Issue Editor
Interests: inflammation; heart; macrophages; cell death; doxorubicin
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer drugs are commonly used to treat tumors. Unfortunately, the majority of cancer drugs (doxorubicin, ponatinib, cisplatin, etc.) induce cardiomyopathy and muscle weakness as a side effect. The exact mechanisms of action of these drugs are far from clear; however, based on current research, it is suggested that increased oxidative stress, inflammation, mitochondrial dysfunction, and cell death are prominent mechanisms involved in the development as well as progression of these diseases. Recent data suggest that researchers are investigating various therapeutic approaches, such as miRNA technology, antioxidative as well as anti-inflammatory drugs, antiapoptotic therapeutic options, cell therapy, and exosomes.
Pharmaceuticals is organizing a Special Issue on the topic of cancer drug toxicity and interventions. In this Special Issue, we invite both original and review articles that cover the current concepts of anticancer-drug-induced toxicity in the heart and muscles. These articles can be of a wider scope, including topics such as oxidative stress, cell signaling, cell death, tissue remodeling, inflammation, and other relevant molecular mechanisms that are involved in anticancer-drug-induced cardiac as well as muscle toxicity. We will also welcome any current therapeutic strategies being investigated to attenuate anticancer-drug-induced side effects in tissues.
Prof. Dr. Dinender K. Singla
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oxidative stress
- cell signaling
- cell death
- tissue remodeling
- inflammation
- molecular mechanisms
- heart
- muscle
- antioxidants
- cell therapy
- exosomes
